ReviewClinical nuclear medicine2013
Parathyroid scintigraphy in renal hyperparathyroidism: the added diagnostic value of SPECT and SPECT/CT.
Review in Clinical nuclear medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 54 citations in OpenAlex.
- SPECT/CT in addition to subtraction parathyroid scintigraphy in hyperparathyroidism: diagnostic performance in a cohort of predominantly end-stage renal disease patients.EJNMMI research · 2025Article
- Risk factors of recurrent secondary hyperparathyroidism after adequate primary surgical treatment.Frontiers in endocrinology · 2023Article
- Use of [European journal of nuclear medicine and molecular imaging · 2022Article
- Is there a consensus between clinical practice guidelines for conventional and molecular nuclear medicine studies in parathyroid pathology?Annals of nuclear medicine · 2021Review
- The EANM practice guidelines for parathyroid imaging.European journal of nuclear medicine and molecular imaging · 2021Article
- Pediatric hyperparathyroidism: review and imaging update.Pediatric radiology · 2021Review
- Article
- Article
- Efficacy of Ultrasound-guided Radiofrequency Ablation of Parathyroid Hyperplasia: Single Session vs. Two-Session for Effect on Hypocalcemia.Scientific reports · 2020Article
- Four Atypical Parathyroid Adenomas Detected by Dual Phase Tc-99m MIBI SPECTMolecular imaging and radionuclide therapy · 2020Article
- Article
- Article
- AbsentOpen access Macedonian journal of medical sciences · 2018Article
- Intraoperative Parathyroid Localization with Near-Infrared Fluorescence Imaging Using Indocyanine Green during Total Parathyroidectomy for Secondary Hyperparathyroidism.Scientific reports · 2017Article
- Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions.The Indian journal of surgery · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 9 institutions in 3 countries.
Funding
Abstract
Secondary hyperparathyroidism (sHPT) is a major complication for patients with end-stage renal disease on long-term hemodialysis or peritoneal dialysis. When the disease is resistant to medical treatment, patients with severe sHPT are typically referred for parathyroidectomy (PTx), which usually improves biological parameters as well as clinical signs and symptoms. Unfortunately, early surgical failure with persistent disease may occur in 5%-10% of patients and recurrence reaches 20%-30% at 5 years. Presently, the use of parathyroid scintigraphy in sHPT is usually limited to the management of surgical failures after initial PTx. This review describes the strengths and limitations of typical (99m)Tc-sestamibi imaging protocols, and highlights the potential benefits of using parathyroid scintigraphy in the initial workup of surgical patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.